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Abstract
Background: Nigeria instituted intermittent preventive treatment for malaria (IPTp) using sulphadoxine-
pyrimethamine (SP) for pregnant women in 2001, but coverage remains low. This study examined the influence of
demand side factors on IPTp coverage.
Methods: Data were collected using a household survey from 1307 women who were delivered of a live baby
within the one-year period preceding the study and through an exit poll from 146 women attending antenatal
clinics (ANC). Data analysis examined coverage based on the national and WHO guidelines for IPTp delivery which
differ with regards to use of IPTp in the last month of pregnancy. Focus group discussions (FGDs) were undertaken
to further explain demand side constraints to coverage.
Results: From the household survey, 96.1% of respondents attended ANC, with most having five or more visits.
Overall IPTp coverage for the first and second doses was 13.7% and 7.3% respectively. The coverage was higher in
the urban areas compared to rural areas (p < 0.01). Amongst women who could have received IPTp based on the
timing of their attendance, only 14.1% and 14.3% were offered the first dose based on national and WHO
guidelines, while 7.7% and 7.5% were offered the second dose respectively giving significant missed opportunities.
Amongst ANC attendees offered first and second doses, 98.9% and 96.9% respectively took the medicine. Only
13.6% and 21.5% of these clients reported taking the drug under direct observation. The low level of coverage was
confirmed by exit survey data, which found coverage of 11.6% and 3.0% for the first and second doses. The FGDs
revealed that women do not have many concerns about side effects, but they take drugs providers give them
because they believe such drugs must be safe.
Conclusion: This study found low coverage of IPTp and high levels of missed opportunities supporting findings
that high ANC attendance does not guarantee high IPTp coverage. Demand side factors such as ANC attendance,
appropriate timing of attendance, and perceptions about side effects were not constraining factors to increased
coverage, raising the need to examine supply side factors.
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Background
Malaria contributes to 11% of maternal deaths in
Nigeria [1]. Parasite prevalence in pregnant women in
Nigeria could be as high as 60-70% [2]. These women
are infected with Plasmodium falciparum, the most
virulent Plasmodium with serious health consequences
including anaemia, impaired foetal growth, still birth,
and premature delivery [3,4].
Intermittent-preventive treatment of malaria in preg-
nancy (IPTp) using sulphadoxine-pyrimethamine (SP)
was approved by the World Health Organization (WHO)
Expert Committee on Malaria for the control of malaria
in pregnancy in areas of moderate to high transmission
[5]. This followed a number of studies documenting its
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effectiveness [4,6,7]. SP was also found to be effective in
increasing birth weight and reducing prevalence of pre-
term deliveries and maternal anaemia in Nigeria [8].
In May 2000, African leaders in Abuja under the Roll
Back Malaria (RBM) partnership set the target that by
2005 at least 60% of all pregnant women who are at risk
of malaria, especially those in their first pregnancies
should have access to chemoprophylaxis or IPT [9]. The
WHO reports that at the end of 2008, 35 of 45 sub-
Saharan African countries had adopted IPTp as national
policy [10]. However, coverage has remained far from
the target in many countries including Nigeria.
In 2001, Nigeria instituted intermittent preventive
treatment using SP for pregnant women in the second
and third trimesters of pregnancy. However, both first
and second dose coverage remains low being 8.0% and
4.6% respectively in Nigeria and 9.9% and 5.4% in
south-east Nigeria [11]. The use of IPTp in Nigeria
involves the administration of at least two curative
doses of SP during pregnancy, regardless of whether the
woman is infected [12]. The first dose is taken after
quickening (WHO 2004) and there should be at least
one month between the two doses. However, although
the WHO guideline allows the administration of IPTp
all through the third trimester, the policy in Nigeria
recommends otherwise, stating that ’the last dose should
be given not later than one month before the expected
date of delivery’ [12]. Direct observed treatment (DOT)
by a qualified health worker was also incorporated to
ensure compliance by pregnant women [13]. Compli-
ance is further enhanced by the single dose treatment of
SP.
Successful deployment of IPTp is dependent on the
utilization rates of antenatal care (ANC) services
amongst pregnant women. Attendance at ANC is high
in most sub-Saharan African countries [5], but up to
25% of pregnant women pay the first visit in the 3 rd
trimester [14]. This may affect the impact of ANC and
IPTp related services as delivery of the second dose of
SP is substantially reduced and envisaged protection for
mother and foetus is lost [15].
A woman that attends ANC needs to do so at appro-
priate times for delivery of IPT, which is best given
when the growth of the foetus is occurring at its highest
velocity (16th - 24th week) as this helps to reduce pla-
cental parasitaemia, foetal growth reduction and the
resultant low birth weight [16]. Whether a woman starts
early or late, each visit should count so that opportu-
nities created by her attendance to ANC are not missed
for the delivery of relevant interventions. However, stu-
dies have shown that missed opportunities abound and
constitute a challenge for IPTp delivery [17,18].
Apart from failure to attend ANC clinics, other identi-
fied barriers to use of IPTp include poor acceptance of
SP because of perceived association of SP with side
effects, abortions and foetal deformities [19-21]. How-
ever, clinical studies have shown such side effects are
uncommon [4,6,7,22].
This study examined whether demand side factors
constrain coverage of IPTp amongst pregnant women.
This enabled the identification of opportunities to inter-
vene to improve coverage. The study also examined the
differences in coverage and demand side barriers
between urban and rural dwellers. These are lacking for
Nigeria where maternal mortality remains high [11].
Methods
Study area
This study was carried out in 2010 in Enugu State,
south-east Nigeria. Enugu state has 17 Local Govern-
ment Areas (LGAs), a total population of 3,257,298 and
an annual population growth rate of 3.0 [23]. Enugu
North and South LGAs (Enugu), which have a com-
bined population of 443,575 were purposively selected
to represent urban areas while Udi LGA which has a
population of 234,002, was selected to represent rural
areas. Udi has 17 public primary health facilities that
offer ANC services while Enugu has 11. The commu-
nities used were selected by simple random sampling
from a list of communities in Enugu and Udi.
Data collection
A household and a facility exit survey were used to elicit
information on coverage, demand side factors that could
explain the level of coverage observed, and the practice
of directly observed treatment with IPTp. In addition,
focus group discussions (FGDs) were undertaken to
further provide qualitative data on demand side con-
straints to coverage.
Household survey
A pre-tested interviewer-administered questionnaire was
used to elicit information from a total of 1307 women
who had pregnancies with live births as outcome in the
one-year period preceding the study. The minimum
sample size required was computed separately for the
urban and rural areas based on a 95% confidence level
and an IPTp coverage of 12.6% and 6.0% in urban and
rural areas of Nigeria, respectively [11]. For each LGA,
three out of eight communities were initially selected by
simple random sampling. In the second stage, women
within each community were initially listed following
visits to their households and a constant proportion of
women from the sampling frame of each community
was randomly selected to ensure a self weighted sample.
Exit poll
All the 28 primary health care facilities providing
antenatal care in the study sites were used. A pre-tested
interviewer administered questionnaire was used to
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collect information from 146 women that had com-
pleted 8 months of pregnancy, and so were no longer
eligible to receive IPTp based on the national guidelines.
The minimum sample size required was determined
based on a confidence level of 95%, an error margin of
0.05, and an IPTp coverage level of 8% for women
receiving antenatal care from a skilled provider in the
southeast region [11]. Since the level of attendance of
ANC varies for different facilities, a proportionate
method was used for determining the sample size for
each facility. The sample for each facility was deter-
mined by weighting the total sample size required with
the relative proportion of clients that the facility handles
- using the total attendance figures for each facility (as
reported by the heads of the facilities) for the week
prior to commencement of data collection as numerator,
and the sum of ANC attendees in all the facilities as
denominator. Half of the required sample for each facil-
ity was selected on each of the two days that facilities
run ANC clinics in a week from the group of women
attending the compulsory general health talk organized
for all women with ANC clinic appointments for the
day.
Focus group discussion
Focus group discussions (FGDs) were held with women
of childbearing age (15-49 years) who delivered live
babies within the one-year period preceding the study.
Four FGDs were held - one for each of the four study
sites. There were 8-10 members in each group and each
FGD lasted between 45 and 60 minutes. The participants
were purposively selected with the help of a community
contact person, so that all sections of each community
were represented. A topic guide, focusing on awareness
about IPTp delivery and factors influencing its uptake by
women, was used to guide the discussions and an electro-
nic voice recorder was used for the interviews.
Ethical considerations
Ethical clearance was obtained from the Research Ethics
Committees of the University of Nigeria Teaching Hospi-
tal Enugu and the London School of Hygiene and Tropical
Medicine, while permission to carry out the study was
obtained from the Primary Health Care Coordinator of
each of the LGA’s and from the heads of facilities used.
All respondents and interviewees were required to sign or
thumb-print a consent form after they had been informed




Data was pooled within the urban and rural areas. Cover-
age was measured by asking standard questions about
IPTp used for Demographic and Health Survey data [11].
Coverage of IPTp was analysed in three dimensions: based
on all respondents (overall coverage), based on all respon-
dents that attended ANC, and based on respondents that
made “timely attendance” or “timely visit” defined here as
attendance to ANC at a time a pregnant woman should be
offered IPTp based on existing guidelines for IPTp delivery.
In order to assess “timely attendance”, respondents were
categorized into groups by matching the information
about the gestational age of pregnancy at the times they
made ANC visits with the national [1] and WHO [5]
guidelines for timing of delivery of IPTp. Based on the
national guideline, a pregnant woman should not be
offered IPT too early (before quickening - before or during
the 4th month) or too late (within the last month of preg-
nancy), and needs a gap of one month between two doses.
Attendance to ANC between these early and late points
was defined as “timely attendance”. For the WHO guide-
lines, the period considered as “timely attendance” extends
through the third trimester. In the case of the WHO
guidelines more women would be expected to meet the
inclusion criterion because the guideline does not restrict
IPTp delivery within the last month of pregnancy. As
shown in Table 1, categories B-D represent those that
should be offered the first dose while only those in cate-
gory C should be offered a second dose. Missed opportu-
nities included women who made timely visits but were
not offered IPTp [17,18]. Data were analysed in STATA
version 11 using the ‘svyset’ commands in order to adjust
for the cluster survey design. The communities/health
facilities were used as the primary sampling units and
urban/rural area as ‘strata’.
Qualitative data analysis
The records of FGDs were transcribed and responses were
categorized into domains representing common themes.
The areas of consensus and divergence in the responses
according to the groups and study areas were determined
for better identification of influences constraining cover-
age. Content analysis was used to categorize responses
into domains representing common themes.
Results
The average age of respondents in the household survey
was 28.3 years (Standard error = 0.11) (Table 2). Most
of the women completed secondary education with the
proportion slightly higher in the urban area. In both
LGAs, most respondents were married. Similarly, the
mean age of respondents for the exit interview was 28.4
years (SE = 0.83); most of them completed secondary
school and were married.
Antenatal care attendance and coverage of IPTp amongst
survey respondents
IPTp coverage amongst all respondents for the first dose
was 13.7% (16.9% in urban areas and 8.6% in rural areas,
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p < 0.01) [Table 3]. Second dose coverage was 7.3% and
higher as well for the urban area though not statistically
significant. Most women interviewed in the household
survey (96.1%) attended antenatal care at least once, with
significantly higher attendance among urban dwellers
(99.3%) than rural dwellers (91%) [p < 0.005]. The major-
ity of women made five or more visits for ANC, though
the share was higher for urban than rural areas (89.2% vs.
78.7%, p < 0.001). Amongst ANC attendees, 1st dose cov-
erage was 14.3% while 2nd dose amongst 1235 respon-
dents that made at least two ANC visits was 7.8%.
Amongst all the women that received antenatal care,
97.3% and 91.5% paid timely visits for the first dose and
up to two doses of IPTp respectively based on the
national guidelines (Table 4). Of these women, 14.1% and
7.7% were offered the first and second doses respectively
giving missed opportunities of 85.9% and 92.3%. More
urban dwellers were offered the first dose (p < 0.01).
Based on WHO guidelines, 99.5% and 95.8% paid timely
visits for the first and up to two doses, respectively, while
14.3% and 7.5% were offered IPTp. Seven and seven
respondents who attended at inappropriate times for
IPTp were offered the first and second doses respectively
based on the national guidelines. However, all sevens
offered the first dose and one of those offered the second
dose were eligible based on the WHO guidelines. Addi-
tional 28 and 54 women, for first and second doses,
respectively, would have also been eligible for these doses
based on the WHO guidelines.
Amongst ANC attendees offered first and second
doses, 98.9% and 96.9% accepted the medicine (Table 3).
The two respondents who did not take the first dose felt
it would affect the baby while all the three that did not
take the second dose felt that the time was too close to
delivery for them to take it.
For the exit survey respondents, overall IPTp coverage
amongst all ANC attendees was 11.6% for the first dose
and 3.0% for the second dose amongst those attending at
least two times (Table 3). Based on the national guide-
lines, the figures for timely attendance for the first and
second doses were 93.8% and 76.5% respectively, and the
coverage amongst them was 12.4% and 4.0%, giving a
missed opportunity of 87.6% and 96.0% respectively
(Table 4). All those that received the first and second
doses took them.
Source of drug for IPTp and practice of directly observed
treatment amongst those who took the drug
Of the household survey respondents who took the
drugs for IPTp, 62.7% and 58.1% obtained the first and
Table 1 Categories for timely attendance
Category Description of category Theoretical implications of timing and adequacy of visits for ANC
A No visit within appropriate time Should not be offered SP
B Only one timely visit Can only receive one dose. The later the visit, the less the period of
protection
C Made at least 2 timely visits that were at least one month apart Can be offered 2 doses of IPTp. Early attendees (those within 5th month)
achieve the best protection
D Up to 2 visits within appropriate time but visits were less than one
month apart to receive 2 doses
Should only receive 1 dose. Period of protection is also affected by the
timing of the earliest visit
Table 2 Socio-demographic characteristics of respondents
Variable Household survey Exit interview
URBAN RURAL Total N = 146
N = 806 N = 501 N = 1307 %
% % %
Age: mean (standard error) 28.4 (0.13) 28.3(0.19) 28.3 (0.11) 28.4 (0.83)
Highest Level of education reached
None 0.4 1.0 0.6 0.7
Incomplete Primary 0.7 2.0 1.2 2.1
Complete Primary 8.3 10.2 9.0 9.6
Secondary + 90.6 86.8 89.1 87.7
Current marital status
Single 3.0 4.0 3.4 4.8
Married 91.2 88.4 90.1 88.4
Widowed 5.3 5.6 5.4 6.2
Divorced/separated 0.5 2.0 1.1 0.7
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second doses free at the health facility respectively
(Table 5). Only 13.6% and 21.5% of these patients
reported taking the first and second doses offered at the
facility under direct observation. For the exit poll, 13
(76.5%) of the 17 respondents that took the first dose of
SP obtained it free at the facility while the rest pur-
chased it at the facility. However, 82.4% took it at home,
while the rest took it in the facility under observation.
Similarly, three out of the four that took the second
dose did so at home while one took it at the facility
under observation. Two of them obtained it at the facil-
ity while the rest purchased it at the facility.
Results of focus group discussions
Only two out of all participants had ever heard of IPTp.
One (from the urban area) heard of it when some visi-
tors to the facility she registered talked about it. The
second woman (from the rural area) heard of it from a
friend in school. Thus, no one heard of IPTp from
health workers. The two who said they knew about it
Table 3 Coverage of IPTp for malaria amongst respondents
Household Survey P* Exit Poll
URBAN RURAL Total
N = 806 N = 501 (N = 1307) N = 146
n(%) [CI] n(%) [CI] n(%) [CI] n(%) [CI]
IPTp Coverage and ANC attendance amongst all respondents
First dose 136 (16.9) [15.2-18.7] 43 (8.6) [5.3-13.4] 179 (13.7) [12.0-15.5] 0.009*
Second dose 71 (8.8) [7.3-10.6] 25 (5.0) [2.5-9.6] 96 (7.3) [5.9-9.8] 0.085
Attended ANC at least once 800 (99.3) [96.7-99.8] 456 (91.0) [89.0-92.7] 1256 (96.1) [95.1-96.9] 0.001*
Attended ANC ≥ 2 times 785 (97.4) [94.8-98.7] 450 (89.8) [87.7-91.6] 1235 (94.5) [92.9-95.8] 0.002* 132 (90.4) [79.3-95.9]
Coverage amongst ANC recipients
First dose amongst those attending at least once
- Offered dose 136 (17.0) [15.3-18.8] 43 (9.4) [6.0-14.6] 179 (14.3) [12.6-16.1] 0.015* 17 (11.6)[5.3-25.6]
- Took drug 135 (98.9) [94.6-99.9] 42 (97.7) [84.2-99.7] 177 (98.9) [94.6-99.8] 0.383 17 (100)
Second dose amongst those attending
- Offered dose 71 (9.0) [7.6-10.7] 25 (5.6) [2.8-10.8] 96 (7.8) [6.3-9.6] 0.134 4 (3.0) [0.9-9.3]
- Took drug 70 (98.6) [88.3-99.9] 23 (92.0) [63.6-98.7] 93 (96.9) [86.1-99.4] 0.144 4 (100)
*P values are for tests of significance for the difference in proportions between urban and rural subgroups. Differences are statistically significant if p < 0.05.
Table 4 Coverage amongst ANC recipients that paid timely visits based on national and WHO guidelines
Household Survey P* Exit Poll
n (%) [CI] n (%) [CI] n (%) [CI] n (%) [CI]
First dose
- Timely attendance 776 (97.0) [95.4-98.1] 446 (97.8) 1222 (97.3) [95.7-98.3] 0.593 137 (93.8) [88.9-96.6]
- Offered dose 131 (16.9) [15.4-18.5] 41 (9.2) [6.0-13.8] 172 (14.1) [12.6-15.7] 0.009* 17 (12.4) [5.6-25.2]
- Missed opportunity 645 (83.1) [81.5-84.6] 405 (90.8) [86.3-94.0] 1050 (85.9) [84.3-87.4] 120 (87.6) [74.8-94.4]
Second dose
- Timely attendance 731 (91.4) [88.9-93.3] 418 (91.7) [87.8-94.4] 1149 (91.5) [89.5-93.1] 0.865 101 (76.5) [69.2-82.6]
- Offered dose 67 (9.2) [7.9-10.6] 22 (5.3) [2.9-9.5] 89 (7.7) [6.4-9.3] 0.066 4 (4.0) [1.2-12.4]
- Missed opportunity 664 (90.8) [89.4-92.2] 396 (94.7) [90.5-97.2] 1060 (92.3) [90.7-93.6] 97 (96.0) [87.6-98.8]
Coverage amongst ANC recipients that paid timely visits based on WHO guidelines
First dose
- Timely attendance 795 (99.4) [98.4-99.8] 455 (99.8) [97.8-99.9] 1250 (99.5) [98.9-99.8] 0.334
- Offered dose 136 (17.1) [15.4-18.9] 43 (9.5) [6.0-14.6] 179 (14.3) [12.6-16.2] 0.015*
- Missed opportunity 659 (82.9) [81.1-84.6] 412 (90.6) [85.4-94.0] 1071 (85.7) [83.8-87.4]
Second dose
- Timely attendance 765 (95.6) [93.6-97.0] 438 (96.1) [90.2-98.5] 1203 (95.8) [93.7-97.2] 0.817
- Offered dose 68 (8.9) [7.4-10.6] 22 (5.0) [2.7-9.2] 90 (7.5) [6.1-9.1] 0.066
- Missed opportunity 697 (91.1) [89.4-92.6] 416 (95.0) [90.8-97.3] 1113 (92.5) [90.9-93.9]
*P values are for tests of significance for the difference in proportions between urban and rural subgroups. Differences are statistically significant if p < 0.05.
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said it was ’something they do to prevent malaria’ but
had no idea what drug is used, how many doses a
woman should take, when in pregnancy it should be
given and how it should be given. The participant from
the rural area however reported that a woman that
books at the eight month of pregnancy should not
receive two doses.
After IPTp was described to participants, some partici-
pants from one of the four discussion groups (rural area)
recalled being given SP (in combination with other
drugs) by health workers during pregnancy for preven-
tion, but not for treatment. Two recalled being asked by
the caregiver to take two tablets first and one later while
another took three at a time and was given a second dose
one month before delivery.
Concerning use of SP during pregnancy, participants
did not see any cause for worry about use of the drug
during pregnancy. Side effects could happen but ’this is
seen in all drugs used for malaria.’ Rather, women are
worried when they do not know the drugs to take; but
they take drugs health workers give them because ‘they
(the health workers) will only give the safe ones.’ They
also did not identify any existing cultural factor that hin-
ders them from going for antenatal care or taking drugs
given to them by health workers. The only concern
expressed by participants in the rural area was that when
women are taking herbal drugs given to them (usually by
the TBA or mothers), they collect and keep the ‘modern
drug’ and may have to wait to finish the herbal one
before taking drugs given to them by antenatal care pro-
viders. Husbands, mothers of pregnant women and their
mothers-in-law were mentioned as the only people who
could influence the decision of a woman to take the drug
or not. Even at that, participants did not consider their
influence significant.
Discussion
The level of coverage of IPTp in the study area was low
despite the fact that a policy has been in existence in
the country for a decade. However, the first dose cover-
age that was found in this study (13.7%) was signifi-
cantly higher than that reported in the DHS 2008 for
the southeast region of the country (c2 = 7.96, p <
0.05), suggesting that further improvements have been
made in coverage in the region. However, there was no
significant difference for the second dose coverage
found when compared with 5.4% coverage documented
in the DHS 2008 (c2 = 3.8, p > 0.05).
It is worthy of note that first dose coverage was lower
amongst women living in rural areas compared to their
urban counterparts. Earlier reports found coverage levels
of 12.6% and 6.0% amongst women living in urban and
rural areas of the country, respectively [11]. This
unequal coverage indicates that access barriers still exist
to higher degrees for those in the rural areas.
The overall low coverage occurs despite the finding
that nearly all women receive antenatal care and most
make enough visits. Higher IPTp coverage has been
reported even in settings with lower ANC attendance
rates [24]. Other authors note that high attendance to
ANC does not translate to high IPTp coverage [15,25].
This study shows that women pay enough visits for ANC
and should be eligible to receive IPTp. Moreover, even
though they do not know enough about IPTp to make
informed demand for it, they make themselves available
enough to receive interventions provided at the facility.
Apart from making the right number of visits, the visits
should be appropriately timed. This study shows that not
only did women go for ANC, most women attended at
appropriate times for the delivery of two doses of IPTp
irrespective of the guideline used for examining atten-
dance. Attendance to ANC was timely for up to two
doses to be offered even when they paid the first visit late
in their pregnancy. Further still, geographic location did
not affect timely attendance amongst ANC attendees.
Yet, even amongst women who paid timely visits, the
coverage was still very low. Similar observations have
been made elsewhere [26]. What abound are missed
Table 5 Source of drug for IPTp and practice of directly observed treatment amongst recipients
1st Dose 2nd Dose
URBAN RURAL Total URBAN RURAL Total
N = 136 N = 43 N = 179 N = 71 N = 25 N = 96
% % % % % %
How drug was obtained
Received free at the health facility 60.0 71.4 62.7 52.9 73.9 58.1
Bought drug at health facility 38.5 26.2 35.6 44.3 26.1 39.8
Bought drug elsewhere 1.5 2.4 1.7 2.9 0 2.2
Where drug was taken
In facility under observation 9.6 26.2 13.6 17.1 34.8 21.5
In facility without observation 1.5 2.4 1.7 1.4 0 1.1
At home 88.9 71.4 84.7 81.4 65.2 77.4
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opportunities, which, if taken advantage of, provide
enough opportunities for increase in coverage. This find-
ing suggests that supply rather than demand side factors
could be responsible for low coverage of IPTp and need
to be examined. The problem of missed opportunities is
further compounded by another supply related issue -
the national guidelines - which make women ineligible
for IPTp during the last month of pregnancy, even
though such a practice is not supported by clinical evi-
dence [5].
A common concern that may affect use of IPTp is that
women may be unwilling to take drugs given to them,
usually because of side effects [19]. This study however
found that women take drugs given to them once it
comes from the health workers, and do not have serious
concerns about side effects which may affect them. Addi-
tionally, they do not think cultural barriers affect their
demand for IPTp. This suggests that demand side con-
cerns are unlikely to be responsible for low coverage and
use of IPTp.
The study found that over three-quarter of those that
took drugs reported that they were allowed to take the
drug home, contrary to the guidelines for IPTp adminis-
tration which stipulate the use of DOT. The findings of
the exit interview corroborate those of the household
survey and similar reports of poor experience of DOT
elsewhere [19,27]. The implications for effectiveness of
deployment of the intervention are significant - women
are poorly covered with the intervention, and for the few
who receive it, its effectiveness is likely to be further
hampered by poor utilization practices which conflict
with recommended guidelines. It would be useful to
determine why limited use of DOT is reported by the
women by exploring supply side practices.
A useful indicator for monitoring improvements in
implementation of the IPTp policy could be the reduc-
tion in missed opportunities for coverage amongst those
who could have received it. With the limited impact of
demand side factors and the need to focus on the chal-
lenges with the primary delivery system, such an indica-
tor may then reflect supply side constraints. However,
research needs to be carried out to determine the useful-
ness of such an indicator and its sensitivity to demand
and supply side changes.
In conclusion, this study found low coverage of IPTp in
the study area which supported findings that high ANC
attendance does not guarantee high IPTp coverage.
Demand side factors such as attendance to antenatal
care, appropriate timing of attendance, and perceptions
about side effects were not significant constraining fac-
tors to increased coverage. The scenario is worsened by
the reported low experience of directly observed treat-
ment strategy amongst respondents. Further research is
required to explore supply side influences to provide bet-
ter understanding for the low coverage with IPTp.
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